MDM2抑制剂在髓系肿瘤中的应用:从基础生物学到骨髓增殖性肿瘤的临床实践
本文综述了MDM2抑制剂治疗髓系肿瘤的机制与临床进展。MDM2-p53环路在AML和MPN中常因MDM2过表达及JAK-STAT信号而功能抑制。早期AML三期试验阴性,但骨髓纤维化研究显示脾、症状及分子反应,提示TP53野生型中的疾病修饰潜力。
要点
- MDM2抑制剂通过重新激活野生型p53发挥治疗作用,在TP53野生型骨髓纤维化中显示脾、症状和分子反应。
- AML早期三期试验未获阳性结果,强调剂量策略、血液学毒性和生物标志物驱动患者选择的重要性。
- 与JAK抑制剂、BCL-2拮抗剂和干扰素联合及适应性平台设计是优化治疗策略的方向。
核心结论
- MDM2抑制剂在TP53野生型骨髓纤维化中显示临床意义的脾、症状和分子反应,具有疾病修饰潜力。
研究设计与样本
- 综述整合了MDM2抑制剂在髓系肿瘤中的机制基础、临床开发、耐药生物学和未来方向。
主要发现
- AML早期三期试验结果为阴性,而近期骨髓纤维化研究显示脾、症状和分子反应。
- TP53突变克隆选择是MDM2抑制剂耐药机制之一。
- 与JAK抑制剂、BCL-2拮抗剂和干扰素的合理联合及适应性平台设计优化了治疗策略。
- 新一代MDM2降解剂旨在克服反馈限制并提高治疗指数。
临床怎么用
- 在TP53野生型骨髓纤维化中可考虑MDM2抑制剂以获得脾、症状和分子反应。
- 治疗需关注剂量策略、血液学毒性及TP53突变克隆选择,并基于生物标志物选择患者。
- 联合JAK抑制剂、BCL-2拮抗剂或干扰素及采用适应性平台设计是可行的临床研究策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacologic targeting of murine double minute 2 (MDM2) represents one of the most compelling strategies for therapeutic reactivation of wild-type p53 in hematologic malignancies. The MDM2-p53 autoregulatory loop is a central regulator of cellular stress responses, and in myeloid neoplasms-including acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN)-p53 is frequently retained but functionally suppressed through MDM2 overexpression and oncogenic signaling, notably via JAK-STAT activation. Over the past decade, successive generations of MDM2 inhibitors have translated structural and mechanistic insights into clinical investigation, yielding critical lessons regarding dosing paradigms, hematologic toxicity, biomarker-driven patient selection, and mechanisms of resistance, including TP53-mutant clonal selection. While early phase III trials in AML were negative, recent studies in myelofibrosis demonstrate clinically meaningful spleen, symptom, and molecular responses, supporting disease-modifying potential in TP53-wild-type settings. Adaptive platform designs and rational combinations with JAK inhibitors, BCL-2 antagonists, and interferons have further refined therapeutic strategies. Emerging MDM2 degraders and next-generation agents aim to overcome feedback limitations and improve therapeutic index. This review integrates mechanistic foundations, clinical development, resistance biology, and future directions, highlighting how decades of basic science have reshaped p53 reactivation into a precision therapeutic paradigm in myeloid disease.
引用
- Al-Ali HK, Heidel ST, Palandri F, et al. MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms. Leukemia. 2026. PMID: 42086932. doi:10.1038/s41375-026-02975-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。